Current clinical experience with nevirapine for HIV infection

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 299-304

  Carr, Andrew ^b   Cooper, David A ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; ENZYME INHIBITION; FEVER; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MOUTH ULCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOMNOLENCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029866906     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_27     Document Type: Conference Paper

References (17)

1. Merluzzi VJ. Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250; 1411-3.
2. Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991; 163: 966-70.
3. Nevirapine Investigator's Brochure. Boerhinger-Ingelheim Pharmaceuticals Inc. 1994.
4. Richman D, Shin CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991; 88: 11241-5.
5. Mellors JW, Dutschman GE, Im GJ, et al. In vitro selection and molecular characterisation of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446-51.
6. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type-1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991; 65: 4887-92.
7. Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type I and synergistic with zidovudine. Antimicrob Agents Chemother 1991; 35; 305-8.
8. Richman DD, Havlir D, Corbeil, et al. Nevirapine resistance mutations of human immunodeficiency virus (HIV) type 1 selected during therapy. J Virol 1994;68:1660-6.
9. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immun Defic Syndrom Related Retrovir 1995;8:141-51.
10. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
11. Larder BA. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodefiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664-9.
12. Richman DD. Nevirapine resistance during clinical trials (abstract). In: Abstracts of the Second International Workshop on HIV Drug Resistance; Noordwijk, June 1993: 26.
13. Carr A, Vasak E, Munro V, Penny R, Cooper DA. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 250-3.
14. de Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169: 1346-50.
15. de Jong M, and the Dutch-Italian-Australian Nevirapine Study Group. Antiviral response to nevirapine monotherapy in nucleoside naive persons. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract PB0847.
16. 3. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract 511B.
17. Fischl MA. Efficacy and toxicities of combination antiretroviral therapies. In: Program of the 2nd International Congress on Drug Therapy of HIV Infection, Glasgow, United Kingdom, November, 1994: Abstract 7.2.